Linked Life Data

17267661

Source:http://linkedlifedata.com/resource/pubmed/id/17267661

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17267661rdf:typepubmed:Citationlld:pubmed
pubmed-article:17267661lifeskim:mentionsumls-concept:C0004561lld:lifeskim
pubmed-article:17267661lifeskim:mentionsumls-concept:C0205282lld:lifeskim
pubmed-article:17267661lifeskim:mentionsumls-concept:C1425349lld:lifeskim
pubmed-article:17267661lifeskim:mentionsumls-concept:C1420809lld:lifeskim
pubmed-article:17267661lifeskim:mentionsumls-concept:C1521840lld:lifeskim
pubmed-article:17267661lifeskim:mentionsumls-concept:C0769707lld:lifeskim
pubmed-article:17267661lifeskim:mentionsumls-concept:C1517333lld:lifeskim
pubmed-article:17267661lifeskim:mentionsumls-concept:C0626649lld:lifeskim
pubmed-article:17267661pubmed:issue2lld:pubmed
pubmed-article:17267661pubmed:dateCreated2007-2-19lld:pubmed
pubmed-article:17267661pubmed:abstractTextB lymphocyte stimulator (BLyS) is crucial for B-cell survival, and the biological effects of BLyS are mediated by three cell surface receptors designated B cell-activating factor receptor (BAFF-R), transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), and B-cell maturation antibody (BCMA). Increased expression of BLyS and its receptors has been identified in numerous B-cell malignancies. We generated a fusion toxin designated rGel/BLyS for receptor-mediated delivery of the recombinant gelonin (rGel) toxin to neoplastic B cells, and we characterized its activity against various B-cell tumor lines. Three mantle cell lymphoma (MCL) cell lines (JeKo-1, Mino, and SP53) and two diffuse large B-cell lymphoma (DLBCL) cell lines (SUDHL-6 and OCI-Ly3) expressing all three distinct BLyS receptors were found to be the most sensitive to the fusion toxin (IC(50) = 2-5 pmol/L and 0.001-5 nmol/L for MCL and DLBCL, respectively). The rGel/BLyS fusion toxin showed specific binding to cells expressing BLyS receptors and rapid internalization of the rGel component into target cells. The cytotoxic effects of rGel/BLyS were inhibited by pretreatment with free BLyS or with soluble BAFF-R, TACI, and BCMA decoy receptors. This suggests that the cytotoxic effects of the fusion toxin are mediated through BLyS receptors. The rGel/BLyS fusion toxin inhibited MCL cell growth through induction of apoptosis associated with caspase-3 activation and poly (ADP-ribose) polymerase cleavage. Our results suggest that BLyS has the potential to serve as an excellent targeting ligand for the specific delivery of cytotoxic molecules to neoplastic B cells expressing the BLyS receptors, and that the rGel/BLyS fusion toxin may be an excellent candidate for the treatment of B-cell malignancies especially MCL and DLBCL.lld:pubmed
pubmed-article:17267661pubmed:languageenglld:pubmed
pubmed-article:17267661pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:citationSubsetIMlld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17267661pubmed:statusMEDLINElld:pubmed
pubmed-article:17267661pubmed:monthFeblld:pubmed
pubmed-article:17267661pubmed:issn1535-7163lld:pubmed
pubmed-article:17267661pubmed:authorpubmed-author:AguiarRicardo...lld:pubmed
pubmed-article:17267661pubmed:authorpubmed-author:RosenblumMich...lld:pubmed
pubmed-article:17267661pubmed:authorpubmed-author:MarksJohn WJWlld:pubmed
pubmed-article:17267661pubmed:authorpubmed-author:HittelmanWalt...lld:pubmed
pubmed-article:17267661pubmed:authorpubmed-author:CheungLawrenc...lld:pubmed
pubmed-article:17267661pubmed:authorpubmed-author:LyuMi-AeMAlld:pubmed
pubmed-article:17267661pubmed:issnTypePrintlld:pubmed
pubmed-article:17267661pubmed:volume6lld:pubmed
pubmed-article:17267661pubmed:ownerNLMlld:pubmed
pubmed-article:17267661pubmed:authorsCompleteYlld:pubmed
pubmed-article:17267661pubmed:pagination460-70lld:pubmed
pubmed-article:17267661pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:meshHeadingpubmed-meshheading:17267661...lld:pubmed
pubmed-article:17267661pubmed:year2007lld:pubmed
pubmed-article:17267661pubmed:articleTitleThe rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.lld:pubmed
pubmed-article:17267661pubmed:affiliationImmunopharmacology and Targeted Therapy Section, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Unit 0044, 1515 Holcombe Boulevard, Houston, TX 77030, USA.lld:pubmed
pubmed-article:17267661pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17267661pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17267661lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17267661lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17267661lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17267661lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17267661lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17267661lld:pubmed